throbber
ENETS Guidelines
`
` Neuroendocrinology 2004;80:394–424
` DOI: 10.1159/000085237
`
` Published online: April 18, 2005
`
` Guidelines for the Diagnosis and
`Treatment of Neuroendocrine
`Gastrointestinal Tumours
`
` A Consensus Statement on Behalf of the European Neuroendocrine
`Tumour Society (ENETS)
`
` U. Plöckinger a G. Rindi b R. Arnold c B. Eriksson d E.P. Krenning e
`W.W. de Herder f A. Goede g M. Caplin g K. Öberg h J.C. Reubi i O. Nilsson j
`G. Delle Fave k P. Ruszniewski l H. Ahlman m B. Wiedenmann a
`
` a
` Department of Hepatology and Gastroenterology, Interdisciplinary Center for Metabolism, Endocrinology, and
`
`Diabetes, Charité-Universitätsmedizin Berlin, Berlin , Germany; b
` Department of Pathology, University of Parma,
` Section for Endocrine Parma , Italy; c Department of Gastroenterology, Philipps-Universität, Marburg , Germany; d
`
`
`Oncology, Department of Medical Sciences, University Hospital, Uppsala , Sweden; e
` Department of Nuclear
`Medicine, Erasmus University Medical Center, Rotterdam , The Netherlands; f
` Department of Internal Medicine,
`
`
`Erasmus University Medical Center, Rotterdam , The Netherlands; g Royal Free Hospital, London , UK; h Uppsala
`University, Department of Endocrine Oncology, Uppsala , Sweden; i
` University of Bern, Institute of Pathology,
` Ospedale S. Andrea, Bern , Switzerland; j Sahlgrenska sjukhuset, Department of Pathology, Gothenburg , Sweden; k
`
`
`Department of Gastroenterology, Rome , Italy; l
` Hôpital Beaujon, Department of Gastroenterology, Clichy , France,
`and m
` Department of Surgery, Gothenburg University, Gothenburg, Sweden
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Key Words
` Neuroendocrine tumour ⴢ Diagnosis ⴢ Histopathology ⴢ
`Surgery ⴢ Cytoreductive surgery ⴢ Biotherapy ⴢ
`Chemotherapy ⴢ Radioreceptor therapy
`
`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` © 2004 S. Karger AG, Basel
` 0028–3835/04/0806–0394$21.00/0
`
`Fax +41 61 306 12 34
`E-Mail karger@karger.ch
`www.karger.com
`
` Accessible online at:
` www.karger.com/nen
`
` Ursula Plöckinger
` Department of Hepatology and Gastroenterology, Interdisciplinary Center for Metabolism,
` Endocrinology and Diabetes, Charité-Universitätsmedizin Berlin
` Campus Virchow-Klinikum, Augustenburger Platz 1, D–13353 Berlin (Germany)
` Tel. +49 30 450 553 552, Fax +49 30 450 7553 552, E-Mail ursula.ploeckinger@charite.de
`
`ARGENTUM
`Exhibit 1032
`
`000001
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` Introduction
` G. Rindi
`
`
` The endocrine tumours of the gastrointestinal tract
`have been attracting the attention of clinicians since their
`very fi rst identifi cation, which paralleled the identifi ca-
`tion of gut endocrine cells.
` The history of enteroendocrine cells and derived tu-
`mours begins with the early development of histology and
`histochemistry, dating back to the end of the 19th cen-
`tury. Unusual cells of gastric [1] and intestinal mucosa
` [2–4] attracted the attention of scientists and, due to their
`chromium salt affi nity [4] , were named enterochromaffi n
`cells [5] . Cells with similar properties were observed in
`other sites of the body [6] and were suggested to be part
`of a complex system exerting a local, ‘paracrine’, action
`via production and secretion of peptides or amines [7] .
`This concept was further revived and supported in the
`1960s by the identifi cation in some of these cells of the
`property of taking up amine precursors which are then
`transformed into amines by intracellular decarboxylation
` [8] .
` At the same time, a non-conventional, epithelial slow-
`growing tumour was identifi ed and defi ned as ‘karzinoide’
`(carcinoid, i.e. carcinoma-like) by Öberendorfer [9] . Some
`of these tumours were then shown to display argentaffi n
`properties [10] , thus establishing a relationship with en-
`terochromaffi n cells [11] .
` As many as 15 highly specialized epithelial cells of en-
`dodermal origin compose the diffuse endocrine system
`(DES) of the gut [12] and are considered the source of gut
`carcinoids and of tumours of the endocrine pancreas.
` Gut DES cells and derived tumours express several
`antigens shared with nerve elements, usually defi ned as
`‘neuroendocrine markers’ [13] . This phenomenon pro-
`vides reason for the term ‘neuroendocrine’ which is wide-
`ly used to connote DES cells and their tumours. The neu-
`roendocrine markers comprise neuron-specifi c enolase
`(NSE) and protein gene product 9.5 (PGP 9.5) [14, 15]
`located in the cytosol, the chromogranins (A, B and C or
`secretogranin) associated with electron-dense granules
` [16, 17] and synaptophysin within small synaptic-like
`vesicles [18, 19] .
` The remarkable heterogeneity of the endocrine cells of
`the gut [20] compose the complexity of derived tumours.
`Besides neuroendocrine markers, multiple hormones are
`in fact produced and, in some instances, also released in
`the bloodstream to determine a hyperfunctional syn-
`drome.
`
` Many attempts have been made in the past few de-
`cades to uniformly classify, diagnose and treat gut endo-
`crine tumours. Unfortunately, because of their rarity, no
`structured practice for diagnosis and therapy has been
`developed, despite increasing knowledge and awareness
`of the subject. The recent introduction of a more struc-
`tured classifi cation of tumours of the diffuse endocrine
`system by the World Health Organisation [21] inspired
`an effort to develop common diagnostic and treatment
`guidelines within Europe. As members of the European
`Neuroendocrine Tumour Society (ENETS), a group of
`clinicians became involved in the study of neuroendo-
`crine tumours and in the treatment of affected patients.
`The following papers are the result of this common effort
`and represent an organized attempt to give evidence-
`based information on this subject.
`
` References
` 1 Heidenhain R: Untersuchungen über den Bau der Labdrüsen. Ark Mik-
`rosk Anat 1870; 6: 368–406.
` 2 Nicolas A: Recherches sur l’épithélium de l’intestine grêle. Int Mschr Anat
`Physiol 1891; 8: 1–8.
` 3 Kultschitzky N: Zur Frage über den Bau des Darmcanals. Arch Mikrosk
`Anat 1897; 49: 7–35.
` 4 Schmidt JE: Beiträge zur normalen und pathologischen Histologie einiger
`Zellarten der Schleimhaut des menschlichen Darm-Kanals. Arch Mikrosk
`Anat 1905; 66: 12–40.
` 5 Ciaccio C: Sur une nouvelle espèce cellulaire dans les glandes de Lieber-
`kühn. CR Soc Biol (Paris) 1906; 60: 76–77.
` 6 Feyrter F: Über diffuse endokrine epitheliale Organe. Leipzig Zentr Inn
`Mediz 1938; 29: 545–571.
` 7 Feyrter F: Über die peripheren endokrinen (parakrinen) Drüsen des Men-
`schen. Wien, Maudrich, 1953.
` 8 Pearse AGE: Common cytochemical properties of cells producing poly-
`peptide hormones, with particular reference to calcitonin and C-cells. Vet
`Rec 1966; 79: 303–313.
` 9 Öberendorfer S: Karzinoide Tumoren des Dünndarms. Frankf Z Pathol
`1907; 1: 426–432.
` 10 Gosset A, Masson P: Tumeurs endocrine de l’appendice. Presse Médicale
`1914; 25: 237.
` 11 Masson P: Carcinoid (argentaffi n-cell tumours) and nerve hyperplasia of
`the appendicular mucosa. Am J Pathol 1928; 4: 181–212.
` 12 Solcia E, Capella C, Fiocca R, Sessa F, LaRosa S, Rindi G: Disorders of
`the endocrine system; in Ming SC, Goldman H (eds): Pathology of the
`Gastrointestinal Tract. Philadelphia, Williams & Wilkins, 1998, pp 295–
`322.
` 13 Bishop AE, Power RF, Polak JM: Markers for neuroendocrine differen-
`tiation. Pathol Res Pract 1988; 183: 119–128.
` 14 Bishop AE, Polak JM, Facer P, Ferri GL, Marangos PJP, Pearse AGE:
`Neuron specifi c enolase: A common marker for the endocrine cells and
`innervation of the gut and pancreas. Gastroenterology 1982; 83: 902–915.
` 15 Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ: PGP 9.5, a new
`marker for human neuroendocrine tumours. Histopathology 1985; 9: 147–
`158.
` 16 Lloyd RV, Wilson BS: Specifi c endocrine tissue marker defi ned by a mono-
`clonal antibody. Science 1983; 222: 628–630.
` 17 Rindi G, Buffa R, Sessa F, Tortora O, Solcia E: Chromogranin A, B and
`C immunoreactivities of mammalian endocrine cells. Distribution, dis-
`tinction from costored hormones/prohormones and relationship with the
`argyrophil component of secretory granules. Histochemistry 1986; 85: 19–
`28.
`
` Management of Neuroendocrine
`Gastrointestinal Tumours
`
` Neuroendocrinology 2004;80:394–424
`
`395
`
`000002
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` 18 Jahn R, Schiebler W, Ouimet C, Greengard P: A 38,000-dalton membrane
`protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 1985;
` 82: 4137–4141.
` 19 Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE: Synaptophysin:
`A marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad
`Sci USA 1986; 83: 3500–3504.
` 20 Rehfeld JF: The new biology of gastrointestinal hormones. Physiol Rev
`1998; 78: 1087–1108.
` 21 Solcia E, Klöppel G, Sobin LH: Histological Typing of Endocrine Tu-
`mours. New York, Springer, 2000.
`
`include hypoglycaemia, VIPoma, and glucagonoma syn-
`drome. Most tumours are initially non-functioning. Ge-
`netic screening for MEN-1 should be offered to family
`members. Those with genetic lesions should be followed
`annually for detection of parathyroid disease, pituitary,
`pancreatic and other tumours [1–4] .
`
`
`
`
`
` Management of Endocrine Foregut
`Tumours
` B. Eriksson
`
`
`
` I. Introduction
`
` Endocrine foregut tumours include tumours originat-
`ing in the stomach, duodenum, pancreas, lung and thy-
`mus. For practical reasons, lung and thymic tumours are
`not included in these recommendations.
` From a clinical viewpoint, endocrine foregut tumours
`can be divided into functioning tumours, associated with
`hormonal symptoms and non-functioning tumours, not
`associated with any hormonal symptoms. Most endo-
`crine tumours are well-differentiated, non-functioning,
`and slowly growing. Some tumours are poorly differenti-
`ated small cell endocrine carcinomas that are rapidly
`growing and have a poor prognosis. The possibility of the
`endocrine tumour being part of a familiar, genetic dis-
`ease, i.e. multiple endocrine neoplasia type 1 (MEN-1),
`should be excluded.
` Comments: MEN-1 is associated with hyperparathy-
`roid hyperplasia/hyperparathyroidism, pancreatic endo-
`crine tumours, pituitary adenomas, thymic, gastric and
`bronchial carcinoids, adrenocortical hyperplasia, and
`also skin fi bromas/lipomas. The mean age of clinical di-
`agnosis has been reported to be around 30 years; how-
`ever, in screened families it is about 15 years. The exact
`incidence is not known, but a prevalence of 0.2 has been
`reported; MEN-1 is probably underdiagnosed [1] . A spe-
`cifi c deletion on chromosome 11q13 is the genetic back-
`ground of the disease. The gene encodes a protein called
`menin, which acts as a tumour suppressor [2, 3] .
` The most common clinical syndrome associated with
`MEN-1 and pancreatic or duodenal endocrine tumours
`is the Zollinger-Ellison syndrome (ZES). Other syndromes
`
` Endocrine Tumours of the Stomach
`
` Epidemiology
` The yearly age-adjusted incidence of gastric neuroen-
`docrine tumours has been reported to be around 0.2 per
`100,000 population [5] . The tumours are probably under-
`diagnosed.
`
` Clinicopathological Staging
` As in other sites of the gastrointestinal tract, neuroen-
`docrine tumours of the stomach are categorized into well-
`or poorly differentiated tumours [6, 7] .
` Well-differentiated tumours are the majority. Besides
`the extremely rare gastrin-producing (G), somatostatin-
`producing (D), or serotonin-producing (EC) cell tumours,
`most well-differentiated tumours are mainly, but not ex-
`clusively, composed of enterochromaffi n-like (ECL) cells
`and are most frequently located in the acidopeptic mu-
`cosa. They are also called ECL-cell carcinoids or ECLo-
`mas and three subtypes of well-differentiated ECL cell
`tumours are recognised [6, 7] .
` Type 1 is the most common NE neoplasm in the whole
`stomach with a relative incidence of 70–85%, and is fre-
`quently small, polypoid, often multiple and usually be-
`nign (WHO group 1). It is secondary to hypergastrinae-
`mia, related to atrophic gastritis (also includes microcar-
`cinoidosis) and is always associated with ECL-cell
`hyperplasia.
` Type 2 is a rare tumour associated with primary hy-
`pergastrinaemia as a manifestation of ZES as part of
`MEN-1. Type 2 tumours appear mostly as multiple be-
`nign polyps (WHO group 1), and are only in exceptional
`cases metastatic (WHO group 2, endocrine carcinoma).
` Type 3 is the second most common NE gastric tumour
`with a relative incidence of 13–20%; it appears sporadi-
`cally without predisposing factors either local (atrophic
`gastritis) or genetic (MEN-1: ZES). It is usually solitary
`and belongs to WHO group 2: Ki-67 1 2%, 1 2 cm in di-
`ameter and infi ltrative growth with metastases both to
`regional lymph nodes and the liver. Less than 5% of these
`tumours can cause the so-called ‘atypical carcinoid syn-
`drome’ due to histamine production.
`
`396
`
` Neuroendocrinology 2004;80:394–424
`
` Plöckinger et al.
`
`
`000003
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` Poorly differentiated tumours are highly malignant
`and belong to WHO group 3, i.e. poorly differentiated,
`small-cell, endocrine carcinomas (PDEC). They are rela-
`tively rare and account for ! 5% of endocrine tumours.
`They are probably underestimated since they may resem-
`ble undifferentiated carcinomas. A positive staining for
`synaptophysin may be the only indicator of endocrine
`differentiation.
`
` Prognosis/Survival
` Type 1 occurs most often in women, with no tumour-
`related death at an overall mean follow-up of 53 months
` [8] . Among type 2 tumours there was 1 tumour-related
`death (49 months after diagnosis) and an overall mean
`survival of 84 months. In the same series, type 3 tumours
`had a mean survival of 28 months and poorly differenti-
`ated only 7 months.
`
` Clinical Presentation
` Small gastric carcinoids rarely give rise to symptoms
`and are diagnosed incidentally or in patients with perni-
`cious anaemia [9] . Larger carcinoids may bleed. Occa-
`sionally, patients may complain of fl ush and present the
`‘atypical carcinoid syndrome’. The ‘atypical carcinoid
`syndrome’ includes severe generalized fl ushing, swelling,
`lacrimation, asthma and diarrhoea, caused by histamine
`production from a gastric endocrine tumour type 3.
`
` Diagnostic Procedures
` 1. Tumour Imaging
` Gastroscopy/endoscopic ultrasonography (EUS), ab-
`dominal ultrasound, contrast-enhanced CT or MRT of
`the abdomen and octreotide scintigraphy.
` Comments: Gastroscopy with multiple biopsies from
`tumour and non-tumour tissue is essential for histopath-
`ological diagnosis to distinguish between the different
`types of gastric tumours and also indicating the size and
`location of the primary tumour. It is also important to
`exclude infection with Helicobacter pylori . CT/MRT and
`octreotide scintigraphy are important for staging of the
`disease in type 3 and poorly differentiated tumours.
`
` 2. Biochemical Diagnosis [9]
` Chromogranin A, gastrin, histamine metabolites in
`urine (with appropriate diet). It is also important to de-
`termine the presence of parietal cell antibodies. MEN-1
`should be excluded by determining ionized calcium, PTH
`and possibly also pituitary hormones.
` Comments: Chromogranin A is the most sensitive
`marker for detection of gastric endocrine tumours (not in
`
`type 1 and 2). Measurement of gastrin will reveal atrophic
`gastritis and secondary hypergastrinaemia. If the patients
`present with fl ush in association with a gastric endocrine
`tumour (type 3), measurement of urinary histamine me-
`tabolites is recommended (elevated in 33% of type 1 and
`80% of type 3 gastric carcinoids). MEN-1 should be con-
`fi rmed in gastric endocrine tumours type 2.
`
` 3. Histopathology
` Haematoxylin and eosin, chromogranin, synaptophy-
`sin, Ki-67.
` Comments: If the diagnosis of a well- or poorly differ-
`entiated endocrine tumour is established by routine his-
`topathology including the staining for chromogranin A
`and synaptophysin, additional staining for Ki-67 should
`always be performed to demonstrate the proliferative ca-
`pacity of the tumour. High Ki-67 ( 1 15–20%) indicates
`poor prognosis.
`
` Endoscopic and Surgical Therapy [10]
` 1.1. Curative Therapy
` Type 1 and 2 tumours (atrophic gastritis or MEN-1).
` Polyps ! 1 cm in size: surveillance once per year; 1–6
`polyps and 1 1 cm in size, endoscopic resection after EUS
`and surveillance; 1 6 polyps and 1 1 cm in size, extension
`to muscularis and/or repeated recurrences: alternatively
`surgical resection or antrectomy (reduces gastrin stimula-
`tion from antral G-cells).
` Malignant development or recurrence despite local
`surgical resection: partial or total gastrectomy with lymph
`node dissection.
` Type 3 and poorly differentiated tumours: partial or
`total gastrectomy with lymph node dissection as recom-
`mended for adenocarcinomas.
`
` Cytoreductive Therapy (Type 3 and Poorly
`Differentiated Tumours)
` There are very few reports on the results with liver
`embolization (not recommended in histamine-produc-
`ing tumours) and radiofrequency (RF) ablation in gastric
`endocrine tumours.
`
` Medical Therapy
` 1. Biotherapy
` 1.1. Somatostatin analogues: In the case of multiple
`ECLomas with atrophic gastritis or ZES/MEN-1, soma-
`tostatin analogues have been shown to induce regression
`of gastric tumours, type 1 and 2 [11] . This scheme, how-
`ever, is not recom mended.
`
` Management of Neuroendocrine
`Gastrointestinal Tumours
`
` Neuroendocrinology 2004;80:394–424
`
`397
`
`000004
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` 1.2. Interferon: Can be tried in disseminated type 2
`and 3 tumours. Experience is limited [9] .
`
` 2. Systemic Chemotherapy
` Chemotherapy should only be used in metastatic dis-
`ease (mainly type 3 and poorly differentiated tumours).
`The combination of streptozotocin (STZ) plus 5-fl uoro-
`uracil (5-FU)/doxorubicin is recommended in less aggres-
`sive tumours and cisplatin/carboplatin plus etoposide in
`poorly differentiated tumours. There are few reports in
`the literature and experience is limited.
`
` Endocrine Tumours of the Duodenum
`
` Epidemiology
` The age-adjusted annual incidence is ! 0.1 per 100,000
`individuals [5] .
`
` Clinicopathological Staging
` According to WHO indications, tumours of the duo-
`denum and upper jejunum are classifi ed together [12] .
` Well-differentiated tumours – carcinoids – are the
`majority. Most of them are mainly, but not exclusively,
`composed of gastrin-producing (G), somatostatin-pro-
`ducing (D) or serotonin-producing (EC) cells. They may
`be either benign and of uncertain behaviour (WHO
`group 1), or low-grade malignant (WHO group 2, carci-
`noma). G-cell tumours are preferentially located in the
`proximal duodenum when non-functioning. When func-
`tioning (gastrinomas) may be found at any site in the
`duodenum and jejunum and are usually multiple when
`associated with MEN-1. D-cell tumours are usually non-
`functioning and may be associated with neurofi broma-
`tosis (Recklinghausen’s disease). Serotonin cell tumours
`are rare. Gangliocytic paragangliomas are observed in
`the ampullary region, are usually benign and only excep-
`tionally low-grade malignant with metastases composed
`of the epithelial component only. Poorly differentiated
`carcinomas belonging to WHO group 3 (small-cell, poor-
`ly differentiated endocrine carcinomas) are relatively
`rare, highly malignant carcinomas of the ampullary re-
`gion.
`
` Prognosis/Survival
` Five-year survival rate for localized disease is 66%,
`regional disease 28%, distant metastases 17%, and all
`stages 51% [5] .
`
` Clinical Presentation
` The majority of patients presenting with dyspepsia are
`diagnosed with duodenal ulcer. In an occasional patient
`anaemia may be a result of bleeding. Most patients are
`diagnosed incidentally.
`
` Diagnostic Procedures
` 1. Tumour Imaging
` Endoscopy, EUS, contrast-enhanced CT or MRT of
`the abdomen, octreotide scintigraphy.
` Comments: Endoscopy with biopsy is essential for his-
`topathological diagnosis to distinguish between the dif-
`ferent types of duodenal tumours also indicating the size
`and location of the primary tumour. CT/MRT and oc-
`treotide scintigraphy are important for staging.
`
` 2. Biochemical Diagnosis
` Chromogranin A, further determination according to
`the clinical picture: gastrin, calcitonin, somatostatin, uri-
`nary 5-HIAA twice (24 h) with appropriate diet.
` Comments: Chromogranin A is the most reliable tu-
`mour marker in endocrine duodenal tumours. The levels
`of other tumour markers will vary depending on the type
`of tumour. Patients with suspected Recklinghausen’s dis-
`ease or ZES secondary to MEN-1 should have an extend-
`ed biochemical work-up.
`
` 3. Histopathology
` Haematoxylin and eosin, chromogranin A, synapto-
`physin, S-100 (gangliocytic paragangliomas only), Ki-67,
`gastrin, somatostatin, serotonin or other hormones, if re-
`quired by the clinical setting.
` Comments: The diagnosis of an endocrine tumour
`should be demonstrated by routine histopathology in-
`cluding stainings for chromogranin A and synaptophysin.
`The staining for specifi c hormones will help to establish
`the type of duodenal tumour and the determination of
`Ki-67 the proliferation rate.
`
` Surgical Therapy
` 2.1. Curative Surgical Therapy
` Small duodenal tumours may be locally resected by
`endoscopy or surgery. Patients with larger tumours should
`undergo pancreatico-duodenal resection (Whipple’s pro-
`cedure). Tumours located in the distal duodenum should
`be removed by duodenal resection.
`
` 2.2. Palliative Surgery
` Similarly as in other types of endocrine tumours, de-
`bulking of liver metastases should be considered.
`
`398
`
` Neuroendocrinology 2004;80:394–424
`
` Plöckinger et al.
`
`
`000005
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
` Cytoreductive Therapy
` Research on cytoreductive therapy in endocrine duo-
`denal tumours is sparse but should be performed in ac-
`cordance with principles applied in other endocrine gas-
`trointestinal tumours. Ablative therapy may be consid-
`ered.
`
` Medical Therapy
` 1. Biotherapy
` 1.1. Somatostatin analogues: somatostatin analogues
`can be used in patients with hormonal symptoms. Expe-
`rience is limited.
` 1.2. Interferon: Interferon can be attempted in pa-
`tients with disseminated disease. However, experience is
`limited.
`
` 2. Systemic Chemotherapy
` Chemotherapy should only be used in metastatic dis-
`ease (depending on tumour proliferation). The combina-
`tion of STZ and 5-FU/doxorubicin is recommended in
`tumours with low to moderate proliferation and cisplatin/
`carboplatin plus etoposide in poorly differentiated tu-
`mours.
` In gastrin-producing tumours, proton pump inhibitors
`should be used to control acid-related symptoms.
`
` Endocrine Tumours of the Pancreas
`
` Epidemiology
` The incidence of clinically detected tumours has been
`reported to be 4–12 per million inhabitants, which is
`much lower than what is reported from autopsy series
`(about 1%) [5, 13] .
`
` Clinicopathological Staging [12, 14, 15]
` Well-differentiated tumours are the large majority of
`which the two largest fractions are insulinomas (about
`40% of cases) and non-functioning tumours (30–35%).
`When confi ned to the pancreas, non-angioinvasive, ! 2 cm
`in size, with ! 2 mitoses per 10 high-power fi eld and ! 2%
`Ki-67 proliferation index these tumours are classifi ed as
`of benign behaviour (WHO group 1) and, with the notable
`exception of insulinomas, are non-functioning.
` Tumours confi ned to the pancreas but 1 2 cm in size,
`with angioinvasion and/or perineural space invasion, or
` 1 2 cm in size, 1 2 mitoses per 20 high-power fi eld or
` 1 2% Ki-67 proliferation index, either non-functioning or
`functioning (gastrinoma, insulinoma, glucagonoma, so-
`mastatinoma or with ectopic syndromes, such as Cush-
`
`ing, hyperkalaemia or acromegaly) still belong to the
`WHO group 1 but are classifi ed as tumours with uncer-
`tain behaviour. The presence of unquestionable signs of
`malignancy like metastases or invasion of nearby struc-
`tures identifi es low-grade malignant carcinomas (WHO
`group 2).
` Poorly differentiated, small-cell carcinomas are rare
`high-grade malignant carcinomas (WHO group 3), pre-
`senting with distant metastases, and display solid struc-
`ture with necrosis, high mitotic/Ki-67 proliferation index
`and frequent hyperexpression/accumulation of p53.
`
` Prognosis/Survival
` The 5-year survival rate was reported to be 60–100%
`for localized disease, 40% for regional disease, 29% for
`distant metastases, and 80% for all stages [5, 13] . In a pub-
`lication from 1993 [16] , the 5-year survival rate for ad-
`vanced EPT approached 60 months from diagnosis.
`
` Clinical Presentation
` Endocrine pancreatic tumours are classifi ed according
`to clinical symptoms into functioning and non-function-
`ing tumours. The non-functioning tumours [17] , i.e. the
`hormonally silent tumours, constitute the largest group,
`about 50%. Next in incidence are the insulinomas [18,
`19] and gastrinomas [20, 21] , constituting about 25 and
`15%, respectively. VIPomas [22, 23] , glucagonomas [24,
`25] , somatostatinomas [26, 27] constitute the remaining
`15%. Patients with malignant tumours may present with
`mixed syndromes, or the tumours may change clinically
`over time (for details, see references).
` Endocrine pancreatic tumours can occur at any age
`with an equal sex distribution. About 15–30% of patients
`have MEN-1. In MEN-1 patients, multiple tumours occur
`syn- or metachronously [1] . MEN-1 pancreatic tumours
`are usually non-functioning in early ages and then after
`the age of 40 may turn into gastrinomas or other function-
`ing tumours. In von Hippel-Lindau’s disease the endo-
`crine pancreatic tumours are usually non-functioning.
`
` Diagnostic Procedures
` 1. Tumour Imaging
` Ultrasonography, EUS, contrast-enhanced CT or
`MRT of the abdomen, MR-angiography for surgical deci-
`sion-making, octreotide scintigraphy.
`
` Comments
` EUS combined with biopsies in experienced hands is
`the most sensitive method to detect pancreatico-duode-
`nal tumours [28] . US, CT and MRI can also be used to
`
` Management of Neuroendocrine
`Gastrointestinal Tumours
`
` Neuroendocrinology 2004;80:394–424
`
`399
`
`000006
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
`detect the primary tumours and metastases [29] . Octreo-
`tide scintigraphy is a routine investigation for both pri-
`mary tumours and metastases [30, 31] . However, smaller
`tumours, especially insulinomas, can be diffi cult to visu-
`alize with this method and intraoperative ultrasonogra-
`phy is still the most sensitive method [32] .
` According to Gibril and Jensen [31] , US can detect
`9%, CT 31%, MRI 30%, angiography 28%, and octreotide
`scintigraphy 58% of possible primary gastrinomas. The
`sensitivities for detection of histopathologically proven
`liver metastases with the different methods are the fol-
`lowing: US 46%, CT 42%, MRI 71%, angiography 62%,
`and octreotide scintigraphy 92%, respectively. (For detec-
`tion of intra- and extrahepatic lesions: US 19%, CT 38%,
`MRI 45%, angiography 40%, and octreotide scintigraphy
`70%.) In conclusion, octreotide scintigraphy has a sensi-
`tivity that exceeds the combination of the others. PET
`with 5-HTP or L -dopa can be an option for detection of
`small tumours [33] .
`
` 2. Biochemistry
` Chromogranin A, insulin, C-peptide, pro-insulin, gas-
`trin, VIP, glucagon, calcitonin, somatostatin.
`
` Comments
` Chromogranin A is a general tumour marker, which is
`increased in almost all different types of endocrine pancre-
`atic tumours [13] . Another general tumour marker is PP,
`which can be elevated in non-functioning tumours but also
`in functioning tumours. For each tumour type, character-
`istic clinical symptoms should lead to measurement of spe-
`cifi c markers such as gastrin, insulin, VIP, glucagon, and
`somatostatin [13] . To establish the diagnosis of insulinoma
`a 12- to 72-hour fast is recommended; a glucagon test may
`also be informative [18, 19] . For the diagnosis of gastri-
`noma, measurement of basal and maximal gastric acid out-
`put is recommended to exclude secondary hypergastrinae-
`mia [20, 34] . A secretin test may support the diagnosis.
`Determination of pituitary hormones, ionized calcium
`and PTH is included in MEN-1 screening [35] . For early
`detection of pancreatic involvement in MEN-1, a meal
`stimulation test with measurements of PP and gastrin can
`be performed. For genetic testing, see Introduction.
`
` 3. Histopathology [14, 36, 37]
` Haematoxylin and eosin, chromogranin A, synapto-
`physin, specifi c hormones (insulin, gastrin, etc.), Ki-67.
`
` Comments
` See previous chapter.
`
` Surgical Therapy
` 1.1. Curative Surgical Therapy of Primary Tumours
` The indications for surgery depend on clinical symp-
`toms, tumour size and location, malignancy and meta-
`static spread. There is a general consensus that curative
`surgery should be aimed for also in metastatic disease,
`including ‘localized’ metastatic disease to the liver [10] .
`Preoperative procedures should include exploration of
`the whole abdominal cavity, intraoperative ultrasonogra-
`phy of pancreas and liver, and transillumination of the
`duodenum in ZES [10, 38–40] . The type of surgical pro-
`cedure depends on the location of the tumour: pancre-
`atico-duodenal resection (Whipple’s operation), distal
`pancreatic resection, tumour enucleation, enucleation in
`combination with resection. If malignancy is suspected,
`lymph node dissection is mandatory.
`
` Comments
` Since the vast majority of insulinomas are benign,
`patients with insulinomas can undergo surgery. Most
`patients are cured by enucleation or pancreatic resec-
`tion. Similarly, surgery is the only treatment that can
`cure gastrinomas. With the knowledge, that most gastri-
`nomas are localized in the pancreatic head or duode-
`num, radical operation may be feasible (Whipple’s pro-
`cedure and lymph node dissection). In the other tumour
`types, radical surgery is the only treatment for cure, al-
`though it is rarely possible at the time of diagnosis [10,
`38–40] .
` The indications for surgery in MEN-1 patients are
`more controversial, since these patients have tumours in
`other endocrine organs and multiple tumours syn- and/or
`metachronously in the pancreatico-duodenal area. These
`patients are very rarely cured for their pancreatico-duo-
`denal tumour by surgery. Surgery is advocated to avoid
`later development of malignancy (tumours 1 2 cm) in
`both functioning and non-functioning cases [41] . Tu-
`mours in the head of the pancreas should be enucleated
`if possible, distal pancreatic resection for caudally-locat-
`ed tumours and duodenotomy for diagnosis and resection
`of duodenal gastrinoma.
`
` 1.2. Curative Surgery of Liver Metastases [42]
` Resection of liver metastases should always be consid-
`ered both in functioning and non-functioning tumours,
`since progression of tumour disease can be delayed. Com-
`plete resection should be aimed for. The type of surgery
`depends on the location of the metastases. The following
`procedures can be chosen: enucleation, one or more seg-
`mental resections, hemihepatectomy or extended hemi-
`
`400
`
` Neuroendocrinology 2004;80:394–424
`
` Plöckinger et al.
`
`
`000007
`
`

`

`198.143.32.1 - 3/22/2016 10:09:43 PM
`University of Chicago Library
`Downloaded by:
`
`hepatectomy. Intraoperative ultrasonography should be
`performed for detection of all liver metastases.
`
` Comments
` Metastatic disease should be confi ned to the liver. Sur-
`gery should be undertaken only if 90% of the tumour’s
`mass can be successfully removed. Liver surgery can be
`done concomitantly with surgery of the primary tumour
`or on a separate occasion. Specifi c anaesthesiological pro-
`cedures and perioperative somatostatin analogue infu-
`sion are indicated to avoid hormonal crises. If feasible,
`cholecystectomy should be performed synchronously, to
`prevent gallstone formation during future somatostatin
`analogue therapy or complications after liver emboliza-
`tion.
`
`travenous infusion of somatostatin analogues is indicat-
`ed. Forced diuresis to prevent hepatorenal syndrome is
`recommended.
`
` 2. Radiofrequen

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket